Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Kessler

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
JAMA Oncology|December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical TrialHans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.
Cancers|February 15, 2022
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic LeukemiaDaniela V Wenge, Klaus Wethmar, Corinna A Klar, et al.
Plos One|August 31, 2016
Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk PredictionMichele Pohlen, Nils H Thoennissen, Jan Braess, et al.
Blood Advances|April 25, 2022
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapseAndrew F Berdel, Leo Ruhnke, Linus Angenendt, et al.
Plos One|January 3, 2018
Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk PredictionMichele Pohlen, Nils H Thoennissen, Jan Braess, et al.
Cancers|June 11, 2020
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.
Scientific Reports|February 19, 2026
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacyKathrin Hessling, Caroline Brand, Christian Schwöppe, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2021
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma StudyIvar Hompland, Stefano Ferrari, Stefan Bielack, et al.
Leukemia|June 12, 2019
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemiaLinus Angenendt, Eike Bormann, Caroline Pabst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2022
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing SarcomaRaphael Koch, Hans Gelderblom, Lianne Haveman, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
JAMA Oncology|December 23, 2020
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical TrialHans-Joachim Schmoll, Lars H Lindner, Peter Reichardt, et al.
Cancers|February 15, 2022
Characteristics and Outcome of Elderly Patients (>55 Years) with Acute Lymphoblastic LeukemiaDaniela V Wenge, Klaus Wethmar, Corinna A Klar, et al.
Plos One|August 31, 2016
Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk PredictionMichele Pohlen, Nils H Thoennissen, Jan Braess, et al.
Blood Advances|April 25, 2022
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapseAndrew F Berdel, Leo Ruhnke, Linus Angenendt, et al.
Plos One|January 3, 2018
Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk PredictionMichele Pohlen, Nils H Thoennissen, Jan Braess, et al.
Cancers|June 11, 2020
First-In-Class CD13-Targeted Tissue Factor tTF-NGR in Patients with Recurrent or Refractory Malignant Tumors: Results of a Phase I Dose-Escalation StudyChristoph Schliemann, Mirjam Gerwing, Hauke Heinzow, et al.
Scientific Reports|February 19, 2026
Trabectedin plus CD13-targeted tissue factor tTF-NGR against advanced relapsed or refractory soft tissue sarcoma: translational data, clinical safety and efficacyKathrin Hessling, Caroline Brand, Christian Schwöppe, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2021
Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: Results from the EUROpean Bone Over 40 Sarcoma StudyIvar Hompland, Stefano Ferrari, Stefan Bielack, et al.
Leukemia|June 12, 2019
The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemiaLinus Angenendt, Eike Bormann, Caroline Pabst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 15, 2022
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing SarcomaRaphael Koch, Hans Gelderblom, Lianne Haveman, et al.
Pageof 8